“Our updated outlook reflects higher anticipated core revenue growth in our life sciences segment as we expect these markets to recover faster than our initial expectations, offset by a slightly more conservative outlook for bioprocessing, given some of the customer-driven timing dynamics we saw in the second quarter.”

In context

“partners, Cepheid's decentralized GeneXpert platform is helping expand testing capacity in affected regions and support faster isolation, treatment, and containment of this deadly virus. Moving to how we are thinking about the second half of the year. We expect third quarter revenue growth to be approximately 2%-3%, which includes an approximately 250 basis point year-over-year headwind from respiratory testing. This implies that core growth excluding respiratory will be approximately 5%, an acceleration versus what we saw in the second quarter. We continue to expect to exit Q4 at the mid-single digit core revenue growth rate as we move past some of the headwinds from the first three quarters of the year. This results in a full year 2026 core revenue growth outlook in the range of 3%-4%. Our updated outlook reflects higher anticipated core revenue growth in our life sciences segment as we expect these markets to recover faster than our initial expectations, offset by a slightly more conservative outlook for bioprocessing, given some of the customer-driven timing dynamics we saw in the second quarter. Additionally, given our second quarter earnings beat and the earlier than anticipated completion of the Masimo acquisition, we're raising our full-year adjusted diluted net EPS guidance to a range of $8.45-$8.60, versus our previous range of $8.35-$8.55. Finally, we expect a third quarter adjusted operating profit margin of approximately 26.5%. To wrap up, we're pleased to deliver better than expected second quarter results and are encouraged by the underlying momentum that is built across our portfolio. Growth accelerated, reflecting improved end markets, strong commercial execution, and the power of our balanced portfolio. Traction on recent product launches also drove growth and share gains across a number of our businesses. At the same time, our teams executed at a high level, and we”